While Eniola’s expertise in **drug resistance prediction (TOPOLOGIX, interface topology, sequence-based ML)** and **pharmacology modeling (neurocascade, CCT)** aligns with the grant’s focus on **novel anti-Klebsiella drug discovery**, the current opportunity appears to prioritize **wet-lab/microbiome-based approaches** (e.g., synthetic biology, multi-omics) over computational methods. However, Eniola’s **sequence-representation models (TOPOLOGIX, ESM-2 embeddings)** could theoretically inform resistance-mutation prioritization or scaffold optimization—potentially bridging gaps in the pipeline. A **collaborative proposal** (e.g., with a microbiology lab) would strengthen fit, but as a standalone grant, the alignment is **moderate** due to the lack of explicit computational drug discovery emphasis.